These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 26042447)
1. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria. Iskrov G; Jessop E; Miteva-Katrandzhieva T; Stefanov R Georgian Med News; 2015 May; (242):46-53. PubMed ID: 26042447 [TBL] [Abstract][Full Text] [Related]
2. Budgetary Impact of Medicinal Therapies for Rare Diseases in Bulgaria. Iskrov GG; Jakovljevic MM; Stefanov RS Folia Med (Plovdiv); 2018 Mar; 60(1):79-91. PubMed ID: 29668449 [TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY Value Health; 2014; 17(1):5-14. PubMed ID: 24438712 [TBL] [Abstract][Full Text] [Related]
4. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020. Schey C; Milanova T; Hutchings A Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518 [TBL] [Abstract][Full Text] [Related]
5. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P Value Health; 2007; 10(5):336-47. PubMed ID: 17888098 [TBL] [Abstract][Full Text] [Related]
6. Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu. Zhang X; Zhou T; Zhou J; Zhang D; Yang Y; Pan J BMC Health Serv Res; 2024 Sep; 24(1):1123. PubMed ID: 39334210 [TBL] [Abstract][Full Text] [Related]
7. Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019). Lee SH; Yoo SL; Bang JS; Lee JH Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32357397 [TBL] [Abstract][Full Text] [Related]
8. Impact of orphan drugs on Latvian budget. Logviss K; Krievins D; Purvina S Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704 [TBL] [Abstract][Full Text] [Related]
9. Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria. Mitkova Z; Dimitrova M; Doneva M; Tachkov K; Kamusheva M; Marinov L; Gerasimov N; Tcharaktchiev D; Petrova G Front Public Health; 2022; 10():1011928. PubMed ID: 36438231 [TBL] [Abstract][Full Text] [Related]
10. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe. Schlander M; Adarkwah CC; Gandjour A Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):171-9. PubMed ID: 25312018 [TBL] [Abstract][Full Text] [Related]
11. Tackling rare diseases at European level: why do we need a harmonized framework? Taruscio D; Trama A; Stefanov R Folia Med (Plovdiv); 2007; 49(1-2):59-67. PubMed ID: 18018471 [TBL] [Abstract][Full Text] [Related]
12. A research roadmap for complementary and alternative medicine - what we need to know by 2020. Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850 [TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis. Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271 [TBL] [Abstract][Full Text] [Related]
14. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review. Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065 [No Abstract] [Full Text] [Related]
15. [Assessment of the pharmaceutical expenditure in Hungary]. Inotai A; Merész G; Kaló Z Acta Pharm Hung; 2010; 80(4):162-72. PubMed ID: 21404477 [TBL] [Abstract][Full Text] [Related]
16. Analysis of the Household and Health Care System Expenditures in Bulgaria. Mitkova Z; Petrova G Front Public Health; 2021; 9():675277. PubMed ID: 34277542 [TBL] [Abstract][Full Text] [Related]
17. High-cost drugs for rare diseases: their expenditure and value based on a regional area-based study. Manea S; Visonà Dalla Pozza L; Minichiello C; Altieri L; Mazzucato M; Bonin M; De Ambrosis P; Borgonovi E; Facchin P Health Serv Manage Res; 2024 Feb; 37(1):52-60. PubMed ID: 36627202 [No Abstract] [Full Text] [Related]
18. Finding legitimacy for the role of budget impact in drug reimbursement decisions. Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251 [TBL] [Abstract][Full Text] [Related]
19. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. Mentzakis E; Stefanowska P; Hurley J Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401 [TBL] [Abstract][Full Text] [Related]
20. Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes. Morrell L; Wordsworth S; Fu H; Rees S; Barker R BMC Health Serv Res; 2017 Aug; 17(1):613. PubMed ID: 28854927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]